Adjuvant VACcination against HPV in surgical treatment of CIN-lesions, a Randomized Controlled Trial
Cervical cancer and its precursors are caused by HPV and occur primarily in women of childbearing age.
The current treatment of precursor stages is surgical removal of part of the cervix. This treatment has a recurrence rate of 8-15%. These women then have to undergo surgical treatment again. In particular, multiple treatments can reduce fertility and cause premature birth and it is also burdensome.
There is an effective and safe vaccine against HPV, but not much is known about the effect of vaccination of women already infected with HPV. The VacCIN study aims to demonstrate that vaccination against the Human Papilloma Virus (HPV) is effective in preventing recurrence of Cervical Intra-epithelial Neoplasia(CIN)II-III lesions, a precursor stage of cervical cancer.
If the vaccine has a preventive effect it will be included in the new national guideline for treatment of recurrent CIN-lesions. At long term, there will be a reduction in cervical cancer cases and less premature births.
More detailed information
Role Erasmus MC: